Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Cerebras shares are drawing attention amid a steep selloff that traders link to TD Cowens price-target cut and continued IPO lockup share releases, with insider selling adding to concerns about near-term supply. Bears point to the companys valuation, growth and customer concentration, while some bulls view the decline as an oversold buying opportunity.

A sharp, persistent selloff is dominating discussion, with traders pointing to analyst caution ahead of earnings and broader market and macro pressures as possible factors. Bears see further downside after repeated failed rebounds, while bulls argue the pullback is an oversold buying opportunity.

OKLO is drawing attention amid a steep selloff, with traders blaming continued ATM share issuance and founder stock sales, alongside concerns that the pre-revenue companys reactor projects remain years from commercialization. Some see an oversold rebound or short-squeeze setup, while others expect further weakness and point to broader pressure on speculative nuclear stocks.

CoreWeaves steep selloff is being driven by concerns about its heavy debt, strained financing and the broader pullback in AI infrastructure stocks. Traders are split between viewing the decline and Goldman Sachs Buy upgrade as an oversold buying opportunity and fearing refinancing pressure, dilution or even bankruptcy; the upgrade has not convinced many skeptics.

DJTs steep decline to fresh lows dominates the conversation, with traders tying the weakness to Trump-related political backlash over Russia and Ukraine and concerns about his approval ahead of the midterms. Many also question the companys business fundamentals, while a smaller bullish group sees the selloff as a buying opportunity or points to possible merger and fusion-related catalysts.

QXOs prolonged slide to fresh lows is being discussed alongside concerns about soft residential roofing and housing demand, elevated rates and inflation, and analyst target cuts. Many traders blame managements limited communication and fear dilution or acquisition-integration risks, while some long-term holders argue the selloff is overdone and view the building-products roll-up as a long-term opportunity.

Disc Medicine shares are drawing attention after Phase 3 APOLLO results for bitopertin met all primary and secondary endpoints in erythropoietic protoporphyria, supporting a planned FDA resubmission after an earlier rejection. Traders are weighing the clinical win and possible path to approval against dilution concerns from a proposed stock-and-warrant offering, with debate over whether the sharp rally can hold.

NuScale shares are under pressure after UBS downgraded the stock, with traders debating concerns about long construction timelines, limited firm customer commitments, and commercialization progress. Some see the selloff as justified execution risk, while others view the downgrade as an overreaction and are buying the dip.

A stronger-than-guided Q3 report and sharply higher 2027 EBITDA outlook are driving CLFs rally. Bullish traders cite the earnings recovery and potential short covering, while skeptics point to debt, reliance on steel prices, and the risk of a sell-the-news pullback.

AGNCs third-quarter results and sharp decline in tangible book value have intensified selling pressure, with traders also criticizing weaker revenue and an earnings miss. Some investors are buying the drop for the high monthly dividend, while others warn that leverage, rate sensitivity, and potential dividend risk make the shares unattractive.